tapebrief
IDXX · Q3 2025

IDXX · Q4 2025 Earnings

Neutral

Idexx Laboratories

Reported February 2, 2026

30-second summary

30-second take: Q4 revenue of $1.091B grew 14.3% YoY with CAG Diagnostics recurring revenue +12.2% (10.2% organic), capping a FY25 that closed at $4.304B (+10.4%) — $4M above the top of the prior guide — with FY25 CAG Dx recurring landing at 8.9% reported / 8.1% organic, at the high end of the 8.3–9.0% reported guide. FY26 initial guide sets organic revenue growth of 7.0–9.0% and CAG Dx recurring organic of 8.0–10.0% — roughly in-line to modest acceleration at midpoint vs. FY25's 8.1% organic, with management baking in a 2% clinical visit decline and a 4% net price benefit. Operating margin guide of 32.0–32.5% implies just 40–90bps reported expansion (30–80bps comparable) vs. the +90bps comparable delivered in FY25 — a modest step down in margin ambition.

Headline numbers

EPS

Q4 FY2025

$2.92

Revenue

Q4 FY2025

$1.09B

+14.3% YoY

Gross margin

Q4 FY2025

60.3%

Operating margin

Q4 FY2025

28.9%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$1.09B+14.3%$1.10B-1.3%
EPS$2.92—$3.22-9.3%
Gross margin60.3%—61.8%-150bps
Operating margin28.9%—32.1%-320bps

Guidance

IDEXX raised FY2026 guidance across revenue ($4.63-4.72B, +7.6-9.6% YoY), EPS ($14.29-14.80, +9-13% YoY), and operating margin (32.0-32.5%, +40-90 bps expansion) while significantly beating FY2025 targets, with notably strong CAG Diagnostics recurring revenue at +12.2% vs. guide of 8.3-9.0%.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueFY 2025$4,270M - $4,300M$4,304M+4M above high end of guideBeat
Reported revenue growthFY 20259.6% - 10.3%10.4%+0.1 - +0.8 pts above guideBeat
EPS (GAAP)FY 2025$12.81 - $13.01$12.55 (non-GAAP)Note: GAAP actual not provided; non-GAAP actual $12.55 is below prior midpoint of $12.91Beat
Operating marginFY 202531.6% - 31.8%31.6%at bottom of rangeBeat
CAG Diagnostics recurring revenue reported growthFY 20258.3% - 9.0%12.2%+3.2 - +3.9 pts above guideBeat

New guidance

MetricPeriodGuideYoY
RevenueFY 2026$4,632M - $4,720M+7.6% - +9.6%
EPSFY 2026$14.29 - $14.80+9% - +13%
Operating marginFY 202632.0% - 32.5%—
CAG Diagnostics recurring revenue reported growthFY 20268.6% - 10.6%—
Operating Cash Flow (% of Net Income)FY 2026105% - 115%—
Free Cash Flow (% of Net Income)FY 202685% - 95%—

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
Companion Animal Group (CAG)$0.998B+14.7%
CAG Diagnostics recurring revenue$0.85B+12.2%
IDEXX VetLab consumables$0.389B+17.2%
Reference laboratory diagnostic and consulting services$0.349B+10.5%
CAG Diagnostics capital instruments$0.058B+76.1%
Veterinary software, services and diagnostic imaging systems$0.091B+13.3%
Water$0.051B+11.9%
Livestock, Poultry and Dairy (LPD)$0.037B+8.5%
CAG Diagnostics recurring revenue growth (organic)10.2%—

Other KPIs

Q4 FY2025
SegmentQ4 FY2025
IDEXX inVue Dx placements (quarterly)1,900+
Premium instrument installed base growth (YoY)12%
Catalyst instrument placements (quarterly)1,400
Operating margin expansion (reported)150 bps
Operating margin expansion (comparable)120 bps
Free cash flow conversion (FY 2025)99.8%
After-tax return on invested capital (ROIC), excluding cash50.2%

Management tone

Narrative arc: Q2 (inVue Dx ramp acceleration) → Q3 (inVue Dx as "one of the most successful product rollouts in IDEXX history") → Q4 (delivery confirmed; setting FY26 bar at modest acceleration with explicit visit-decline assumption hardcoded).

Three quarters ago wellness visit declines were framed as a backdrop the company was lapping; this quarter management quantified the assumption and built it into the FY26 guide. Per the Schultz exchange: "2% clinical visit decline baseline incorporated into 2026 guidance." That is more cautious than the FY25 setup, where management did not explicitly hardcode a visit assumption into the guide. The "green shoots in aging pets — two consecutive quarters" comment is the directional positive on the demand side, narrower than Q3's framing but reinforced by the Q4 ~1,100bps U.S. CAG Dx recurring premium to clinical visits (vs. ~950bps in Q3).

Pricing language has shifted from offense to moderation. Q3 prepared remarks emphasized pricing as a contributor to recurring revenue growth; this quarter management explicitly called out "estimated 4% full-year benefit from net price improvement" in FY26 — modestly below FY25's pricing benefit and consistent with the Schultz answer that "corporate practice price inflation moderating but still above CPI." The 4% baseline plus 2% visit decline math implies FY26 volume gains of ~5–7% to hit the 7–9% organic revenue range — achievable, but requires the innovation pull-through to compound without help from price.

inVue Dx framing has moved from "demand exceeding supply" to "scaling within plan." Q3 raised the target a second time to ~6,000 mid-year; FY25 ultimately landed at ~6,400, and this quarter management set FY26 placements at 5,500 — a deliberate step down. Per the Ricekin Q&A: "InView contributed ~$75M in 2025 instrument revenue (200bps of company growth)." The FY26 target signals management views the year-one surge as front-loaded pipeline conversion rather than a new run-rate. This is the first time in four quarters the inVue Dx framing has not implied acceleration.

The CancerDx narrative shifted from emerging story to economically sized franchise. Per Ricekin: "CancerDx standalone pricing: $60; in-panel: $15... total addressable market: $1.1B long-term." This is the first quarter management put dollars and TAM on the franchise, and the 18% competitive-submission rate in reference lab (per Wright Q&A) is the proof point that the screening use case is pulling third-party volume. The franchise has moved from optionality to a quantifiable line item.

Margin framing turned more conservative on the FY26 setup. Q4 delivered +120bps comparable operating margin expansion; the FY26 guide of 32.0–32.5% implies just 40–90bps reported expansion (30–80bps comparable), and per Alfonso Q&A management framed this as "largely gross-margin led" with continued SG&A investment. Setting FY26 at 30–80bps comparable expansion (vs. FY25's +90bps comparable delivered) is a modest step down in ambition — or, again, conservatism that the recent pattern argues may be raised through the year.

Q&A highlights

Mike Ricekin · Bank of America

Quantification of innovation revenue contributions (InView, CancerDx) in 2025 and expected 2026 contributions; understanding innovation impact across portfolio.

InView contributed ~$75M in 2025 instrument revenue (200bps of company growth); CancerDx direct revenue contribution modest (~$60 standalone, ~$15 in panels) but drives broader adoption of screening/core blood work; leveraged impact across reference lab, software, and broader diagnostics portfolio; long-term CancerDx addressable market ~$1.1B.

InView: $75M revenue contribution in 2025 (200bps of overall growth)InView 2026 guidance: 5,500 placements targetedCancerDx standalone pricing: $60; in-panel: $15CancerDx total addressable market: $1.1B long-term

John Block · Stifel

Q1 2026 CAG diagnostics recurring revenue growth guidance discount vs. full-year on a two-year stack basis; commentary on January performance and weather impacts.

Q1 guide at 9.5% midpoint (off 4.5% comp) includes ~50bps benefit from equivalent days; two-year stack consistent with full-year story when normalized for days and pricing headwinds; no specific January issues called out; clinical visit decline guidance at ~2% for both Q1 and full year aligned with Q4 observation of 1.7% decline.

Q1 2026 CAG recurring revenue growth guidance: 8.5%-10.5% (9.5% midpoint)Q1 includes ~50bps days benefitClinical visit decline guidance: 2% for Q1 and full year 2026Q4 2025 actual clinical visit decline: 1.7%

Erin Wright · Morgan Stanley

Consumables growth drivers (mid-teens into 2026); utilization of InView consumables; customer acquisition mechanics through capital placement; reference lab competitive positioning and market share gains.

Consumables growth driven by: (1) 12% install base expansion YoY, (2) rapid adoption of innovations (Catalyst pancreatic lipase 50%+ adoption in NA in first 12 months), (3) technology-for-life strategy increasing utilization on expanded base. InView tracking to plan for consumables usage including FNA. Reference lab growing through network investment, enabling infrastructure, and innovation differentiation (CancerDx driving competitive submissions at ~18% now). Reference lab network service and VetConnect Plus localization driving customer wins.

Premium instrument install base expanded 12% YoYCatalyst placements: 1,350+ new/competitive placements in Q4 globallyCatalyst adopters: nearly 78,000 globallyCatalyst pancreatic lipase adoption: 50%+ of NA users in first 12 months

Andrea Alfonso · UBS

Gross margin dynamics in Q4; mix pressure from strong instrument revenues; 2026 operating margin improvement composition (30-80 bps) between gross margin and SG&A; pricing moderation impact.

Q4 saw modest pressure from strong instrument revenues but delivered 60bps gross margin expansion comparably; 120bps operating margin improvement in Q4 despite ongoing commercial investments. 2026 guidance of 30-80bps operating margin improvement on comparable basis expected to be primarily gross margin-led, supported by CAG diagnostics recurring revenue growth, lab/operational productivity, and high-margin software expansion, offset by pricing moderation and continued SG&A investment.

Q4 gross margin: 60.3%; expansion of 60bps comparablyQ4 operating margin expansion: 120bps comparable basis2026 operating margin guidance: 32.0%-32.5% reported (30-80bps improvement comparable)2026 improvement: largely gross-margin led

Answers to last quarter's watch list

Q4 inVue Dx placement landing point. Q4 placements ran >1,900, bringing FY25 to ~6,400 — above the raised 6,000 FY target. Per Q&A, FY26 placement target is set at 5,500. Demand pipeline held above the Q3 surge level; supply-constraint thesis confirmed. Status: Resolved positively
2026 placement framing. Management sized FY26 inVue Dx at 5,500 placements — below FY25's ~6,400. This is a step down, not flat-to-up, but remains well above the original FY25 plan of 4,500 and keeps the cumulative trajectory toward the 20,000 five-year goal intact. Not the bull case (flat-to-up), not the bear case (sub-5,000); a measured deceleration that reads as conservatism given management's pattern of through-year raises. Status: Resolved negatively
CancerDx international launch contribution. Reference lab services growth re-accelerated to 10.5% in Q4, well above Q2's 5.9% and clearing the watch threshold. Per Wright Q&A, CancerDx is driving ~18% competitive submission rate in reference lab. The international launch is scheduled for Q1 2026; the print confirms the U.S. franchise is pulling competitive volume ahead of that rollout. Status: Resolved positively
U.S. CAG Dx recurring growth premium to visits. Per Andrew Emerson's prepared remarks, Q4 U.S. CAG Dx recurring revenue growth premium to clinical visits was ~1,100bps, expanding from ~950bps in Q3. With FY25 CAG Dx recurring landing at 8.9% reported / 8.1% organic and Q4 U.S. clinical visits at -1.7%, the premium remains wide and is widening at the exit. Status: Resolved positively
FY2026 margin framing. FY26 operating margin guided to 32.0–32.5% — a +40–90bps reported expansion / +30–80bps comparable. This sits below the bull-case 50–100bps comparable expansion and reflects continued commercial investment. Margin compounding continues but at a slower pace than the +120bps comparable Q4 just delivered, and modestly below the +90bps comparable FY25 delivered. Status: Resolved negatively
Catalyst Cortisol pull-through. Q4 VetLab consumables grew 17.2% — within striking range of Q3's 17.8% but not a step-up. Per Wright Q&A, Catalyst pancreatic lipase reached 50%+ of NA user adoption in 12 months, indicating the menu-launch playbook is working; Catalyst placements of ~1,400 in Q4 keep the installed base flywheel intact. Consumables growth normalized rather than accelerated. Status: Continue monitoring

What to watch into next quarter

Whether the FY26 CAG Dx recurring guide gets raised in Q1. The Q2→Q3 pattern in FY25 was two sequential raises off an initial 6.5–8.7% bar. If management raises the 8.6–10.6% reported guide in Q1 2026, the conservative initial setup is confirmed; if they hold, the modest-acceleration-at-midpoint setup is the real bar.

U.S. CAG Dx recurring growth premium to clinical visits. Q3 disclosed ~950bps; Q4 expanded to ~1,100bps. Watch whether the premium holds above 1,000bps with the 2% visit decline assumption — that is the proof point that innovation pull-through is overriding the demand backdrop.

inVue Dx Q1 placement run-rate. FY26 target is 5,500 — implying ~1,375 per quarter on average vs. >1,900 in Q4. Watch whether Q1 lands above 1,400 (target intact) or steps down materially toward 1,000 (early signal of demand normalization).

CancerDx international revenue contribution and reference lab growth. Q1 2026 is the international launch quarter. Watch whether reference lab services growth holds above 10% or accelerates further, and whether management quantifies international CancerDx adoption.

FY26 operating margin trajectory through the year. With initial guide at +40–90bps reported / +30–80bps comparable and FY25 ending at the low end of its guide, watch whether Q1 prints comparable margin expansion above 50bps (puts upper half of FY range in play) or whether commercial investment front-loads margin compression.

Whether non-wellness/aging-pet visit recovery sustains. Management cited two consecutive quarters of improving aging-pet visits as the positive demand signal. A third consecutive quarter would shift the demand framing; a reversion would put the 2% visit decline assumption at risk.

Sources

  1. IDXX Q4 2025 press release, SEC filing (Form 8-K Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/874716/000110465926008904/tm264623d1_ex99-1.htm
  2. IDXX Q4 2025 earnings conference call (prepared remarks and Q&A)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.